HSV-1, ICP34.5 and ICP47 deleted, US11 promoted,
armed with hGM-CSF
Successful Phase II study on metastatic melanoma, using
Amgen bought BioVex for $1B (2011), renamed produc...
failed conventional therapies. The
objective of this initial trial was to
find the optimal tolerated dose,
determine the spectrum of cancers
sensitive to the viruses as well as
evaluate their epide...